Rhythm Pharmaceuticals, Inc. (RYTM) is a Biotechnology company in the Healthcare sector, currently trading at $87.28. It has a SharesGrow Score of 49/100, indicating a mixed investment profile with 2 out of 7 criteria passed.
Analyst consensus target is RYTM = $140 (+60.4% upside).
Valuation: RYTM trades at a trailing Price-to-Earnings (P/E) of -29.6 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.36.
Financials: revenue is $190M, +113.8%/yr average growth. Net income is $197M (loss), growing at -5.8%/yr. Net profit margin is -103.6% (negative). Gross margin is 89.7% (-1.3 pp trend).
Balance sheet: total debt is $246M against $139M equity (Debt-to-Equity (D/E) ratio 1.77, leveraged). Current ratio is 4.41 (strong liquidity). Debt-to-assets is 51.2%. Total assets: $481M.
Analyst outlook: 20 / 20 analysts rate RYTM as buy (100%) — strong consensus.
SharesGrow 7-Criteria breakdown: Value 78/100 (Pass), Growth 58/100 (Partial), Past 0/100 (Fail), Health 33/100 (Fail), Moat 66/100 (Partial), Future 100/100 (Pass), Income 10/100 (Fail).
